News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA OKs Boehringer Ingelheim Corporation/Eli Lilly and Company (LLY)'s Tradjenta as Add-on to Insulin


8/20/2012 7:02:28 AM

Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Co. (LLY:Quote) said Friday that the U.S. Food and Drug Administration has approved a supplemental new drug application, or sNDA, for Tradjenta tablets for use as add-on therapy to insulin. Tradjenta (linagliptin) is a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. The drug can be used as monotherapy or in combination with other commonly prescribed medications for type 2 diabetes, such as metformin, sulfonylurea, pioglitazone or insulin. Tradjenta should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis (increased ketones in the blood or urine).


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES